A Phase 2 interventional study of Faropenem Medoxomil in Otitis Media, sponsored by Replidyne. Completed at 2 sites in 2 countries. Open to participants aged 6 Months to 7 Years. Per ClinicalTrials.gov, last updated 2008-02-08.
Sponsored by Replidyne · Phase 2, Interventional, and Treatment
The study will be conducted in infants and children with acute otitis media, 6 months to less than 7 years old, in Costa Rica and Israel. The primary objective of this trial will be to describe bacteriologic efficacy in those with initial culture positive specimens with different dosages of faropenem
The study will be conducted in infants and children with acute otitis media, 6 months to \<7 years old, in Costa Rica and Israel. Faropenem is to be used as therapy for both simple and complicated AOM.
246 studies on the registry are indexed under Otitis; 21 are open to participants now.
This study's enrollment of 328 is above the median of 126 across 173 interventional studies indexed under Otitis.
Browse Otitis studies →Replidyne is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
To evaluate bacteriologic efficacy
To describe investigator assessment of clinical response
This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Replidyne